Superior Group of Companies (SGC) Q1 2026 earnings review
Profitability Recovers, But Segments Tell Divergent Stories
Superior Group of Companies (SGC) returned to profitability in 26Q1, posting $0.8M in Net Income compared to a $0.8M loss a year ago. Revenue grew a modest 2.8% YoY to $140.9M. However, looking beneath the consolidated numbers reveals extreme divergence. Branded Products carried the entire quarter with a 33% surge in EBITDA, while Healthcare Apparel profitability collapsed and Contact Centers continued to bleed revenue. Management maintained FY26 guidance, implying a heavily back-end weighted year for growth and earnings.
🐂 Bull Case
SG&A expenses were held essentially flat YoY ($50.4M vs $50.1M) despite a $3.8M increase in sales. This operating leverage allowed EBITDA to accelerate 36% YoY to $4.8M.
The company's largest segment is structurally outperforming. Sales grew 5% and EBITDA surged 33%, validating management's aggressive sales force expansion and strategic market share capture during the downturn.
🐻 Bear Case
Management touted 'improved underlying profitability,' but the Healthcare segment contradicts this. Segment EBITDA collapsed 85% YoY, dropping the margin to a microscopic 0.8%.
Contact Center revenue decelerated further, down nearly 8% YoY. The segment has failed to outpace prior-year customer losses with new pipeline conversions.
⚖️ Verdict: ⚪
Neutral. SGC is executing well on controllable costs and its core Branded Products business is thriving. However, severe weakness in Healthcare margins and Contact Center revenue volumes add significant execution risk to their back-end loaded FY26 guidance.
Key Themes
Branded Products as the Growth Engine
Branded Products was the sole driver of profitability growth in 26Q1. Sales increased 5.1% YoY to $90.9M, while segment EBITDA surged 33% to $7.6M. The segment margin expanded to 8.4% from 6.6% a year ago, proving that prior investments in the sales force and technology are yielding sustainable operating leverage.
Healthcare Apparel Margin Collapse Contradicts Narrative
Despite management's claim of 'healthier business mix' and 'improved underlying profitability,' Healthcare Apparel operating metrics were disastrous. While revenue grew 4.8% to $28.6M, segment EBITDA fell 85% to just $226k. The segment EBITDA margin compressed from a historically weak 5.6% in 25Q1 down to 0.8% in 26Q1. This suggests severe pricing pressure, elevated tariff impacts, or mismanaged inventory costs.
Contact Center Revenue Reversing
The Contact Center segment continues to bleed top-line volume. Revenue dropped 7.8% YoY to $22.3M. While EBITDA held relatively stable ($2.6M vs $2.8M YoY) due to aggressive cost-cutting, the segment cannot shrink its way to long-term prosperity. Management's prior claims of a 'record pipeline' have yet to materialize in the actual revenue prints.
Cost Management Offsets Weakness
The $13 million annualized cost savings program initiated in 2025 is clearly holding. SGC successfully held total SG&A expenses flat YoY at $50.4M, even as total revenue increased by nearly $4M. This tight expense control is the primary reason the company was able to flip from a net loss to a net profit in Q1.
AI Integration Driving Segment Efficiency
Management continues to rely heavily on AI to protect margins. SGC is utilizing proprietary implementations of 'Guru Assist' for real-time agent guidance, accent smoothing, and noise cancellation in Contact Centers. In Branded Products, AI agents are being deployed to automate labor-intensive product selection and mockups, creating a direct competitive advantage over smaller, less capitalized peers.
Ongoing Macro & Geopolitical Volatility
Management explicitly cited that 'macro and geopolitical conditions remain difficult to predict and are weighing on customer spending in certain categories.' This ongoing uncertainty makes SGC's back-end loaded 2026 guidance highly vulnerable to sudden shifts in corporate spending or retail consumer confidence.
Other KPIs
Stable. The company maintained a solid cash position of $23.2M, down only slightly from $23.7M at year-end. Total debt (current + long term) decreased sequentially from $93.7M at year-end to $87.3M. This gives the company sufficient liquidity to fund its dividend and any opportunistic M&A.
Reversing. SGC generated $9.4M in operating cash flow in 26Q1, a massive reversal from the $2.0M cash burn in the prior year quarter. This was largely driven by a $19.4M sequential drawdown in Accounts Receivable, indicating strong collections and working capital management.
Guidance
Stable. Management reaffirmed full-year revenue guidance. The midpoint ($578.5M) implies a modest 2.2% YoY growth rate over FY25's $566.2M. With 26Q1 delivering 2.8% growth, SGC is currently tracking slightly ahead of this target, though performance is highly dependent on the Branded Products segment.
Stable. EPS guidance was confirmed, implying a 17% to 43% acceleration from the $0.46 generated in FY25. With only $0.06 delivered in Q1, achieving this target requires an aggressive earnings ramp in Q3 and Q4. Management explicitly noted that performance will be 'more heavily weighted to the back half of 2026.'
Key Questions
Healthcare Apparel Margin Collapse
Healthcare Apparel revenue grew nearly 5%, but EBITDA fell 85%. Was this due to aggressive pricing to clear inventory, unexpected tariff impacts, or higher marketing spend? How do you restore profitability in this segment?
Contact Center Pipeline Conversion
Contact Center revenues fell 8% YoY. You previously discussed a 'record pipeline' and early 2026 wins. Exactly when will these new accounts offset churn and return the segment to positive YoY revenue growth?
Back-Half Execution Risk
Your FY26 guidance implies significant acceleration in EPS during the second half of the year. Beyond historical seasonality, what specific contracts or cost levers give you confidence in hitting the $0.60 midpoint?